ImmunityBio Files 8-K: Other Events & Financials
Ticker: IBRX · Form: 8-K · Filed: Nov 19, 2024 · CIK: 1326110
| Field | Detail |
|---|---|
| Company | Immunitybio, Inc. (IBRX) |
| Form Type | 8-K |
| Filed Date | Nov 19, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, financials, corporate-actions
Related Tickers: IBIO
TL;DR
IBIO filed an 8-K on Nov 19, 2024, covering other events and financials. Check for updates.
AI Summary
ImmunityBio, Inc. filed an 8-K on November 19, 2024, reporting other events and financial statements. The company, formerly known as NantKwest, Inc., is incorporated in Delaware and headquartered in San Diego, California.
Why It Matters
This filing provides updates on significant company events and financial reporting, which are crucial for investors to assess the company's current status and future prospects.
Risk Assessment
Risk Level: low — This is a routine filing reporting on events and financials, not indicating immediate significant risk.
Key Players & Entities
- ImmunityBio, Inc. (company) — Registrant
- November 19, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- San Diego, California (location) — Principal Executive Offices
- NantKwest, Inc. (company) — Former Company Name
- Conkwest, Inc. (company) — Former Company Name
- ZelleRx Corp (company) — Former Company Name
FAQ
What specific 'Other Events' are being reported in this 8-K filing?
The filing indicates 'Other Events' as an item information, but the specific details of these events are not provided in the provided text snippet.
When was ImmunityBio, Inc. previously known as NantKwest, Inc.?
The filing states the date of the name change from NantKwest, Inc. to ImmunityBio, Inc. was July 13, 2015.
What is the Standard Industrial Classification (SIC) code for ImmunityBio, Inc.?
The SIC code listed for ImmunityBio, Inc. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
What is the fiscal year end for ImmunityBio, Inc.?
The fiscal year end for ImmunityBio, Inc. is December 31 (1231).
What is the SEC file number for ImmunityBio, Inc.?
The SEC file number for ImmunityBio, Inc. is 001-37507.
Filing Stats: 441 words · 2 min read · ~1 pages · Grade level 9.7 · Accepted 2024-11-19 08:01:45
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share IBRX The Nasdaq Global Select
Filing Documents
- ibrx-20241119.htm (8-K) — 29KB
- ibrx-202411198xkexhibit991.htm (EX-99.1) — 19KB
- ib_logoxfinalxcolorx02x2021.jpg (GRAPHIC) — 226KB
- 0001326110-24-000115.txt ( ) — 486KB
- ibrx-20241119.xsd (EX-101.SCH) — 2KB
- ibrx-20241119_lab.xml (EX-101.LAB) — 21KB
- ibrx-20241119_pre.xml (EX-101.PRE) — 12KB
- ibrx-20241119_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On November 19, 2024, the Company issued a press release regarding new data from its ongoing QUILT 3.032 study. A copy of the press release is filed as Exhibit 99.1 and incorporated by reference. Section 9 – Financial Statements and Exhibits.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description of Exhibit 99.1* Press Release dated November 19, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). _______________ * Filed herewith.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNITYBIO, INC. Registrant Date: November 19, 2024 By: /s/ David C. Sachs David C. Sachs Chief Financial Officer